Predict How Any Patient Will Respond To Any Therapy
Next-generation AI simulates drug-patient outcomes across Indian biology in-silico so every clinical development decision is backed by evidence — accelerating trial timelines by up to 40% and replacing physical control arms.
The 10x Clinical Trial Deficit
India carries 17–20% of the world's disease burden but accounts for under 1.5–3% of global clinical trials. Existing trial protocols, predictive risk tools, and dosage regimes are built and validated almost entirely on Western or East Asian patient cohorts.
This population-calibration mismatch creates severe clinical hazards: drug clearance rates differ, adverse events go unpredicted, and standard-of-care control arms recruited in India behave biologically differently from foreign trial baselines.
Our Solution: Silicon Arm bridges this divide by generating high-fidelity, population-calibrated virtual patients and simulating multi-year disease progression trajectories in-silico — providing biopharmaceutical sponsors and clinical investigators with reliable, explainable decision support before physical trials begin.